<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05111392</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0823</org_study_id>
    <secondary_id>Abbott Nutrition (EAS)</secondary_id>
    <nct_id>NCT05111392</nct_id>
  </id_info>
  <brief_title>Hydration Dynamics and Influence of Beverage Composition</brief_title>
  <official_title>Hydration Dynamics and Influence of Beverage Composition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study examines interactions between fluid availability in the gut and fluid retention in&#xD;
      the body. The relative rate of fluid uptake, the expansion of the plasma volume, and percent&#xD;
      of fluid retained by the body will be measured in response to ingestion of beverages of&#xD;
      different composition. Healthy, euhydrated adults will be studied. The results will help&#xD;
      establish formulations of beverages that sustain if not promote acute euhydration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a randomized order for beverage treatments at three separate trials, subjects will&#xD;
      ingest 1 Liter of one of three beverages in 10 minutes: water, a beverage with 2.5% glucose&#xD;
      with 45 mmol sodium/L, or a beverage with 1.7% glucose with 60 mmol sodium/L. Before and&#xD;
      repeatedly for 2 h after ingestion of the beverage, blood samples will be drawn for&#xD;
      assessments of D2O, Hb, Hct, osmolality, sodium, and glucose. The rate of appearance of D2O&#xD;
      will be evaluated using the area under the curve, the slope of the appearance, and half time&#xD;
      to plateau. Comparisons will be made between beverages for indices of the rate of appearance&#xD;
      of D2O, the change in PV over time, and cumulative urine excreted. The cumulative urine&#xD;
      produced will be used to calculate a modified BHI for the two glucose-electrolyte beverages&#xD;
      and water for comparison with 1.0 (expected for no beverage effect). We hypothesize faster&#xD;
      absorption (D2O appearance rate), and better overall hydration (expanded PV and higher&#xD;
      modified BHI) will occur for beverages containing glucose and sodium compared to water.&#xD;
      Further, we hypothesize that of the electrolyte beverages, the beverage with higher sodium&#xD;
      content will promote greater overall hydration (less urine excreted) than the beverage with&#xD;
      lower sodium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Mixed model.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Beverages will have similar color, flavoring, and taste.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of appearance of deuterium in the plasma for placebo</measure>
    <time_frame>2 hours</time_frame>
    <description>Measure the rate of fluid uptake by the gut using appearance of deuterium oxide, or D2O, in the blood after ingesting a fixed volume of placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of appearance of deuterium in the plasma for oral rehydration solution 1.</measure>
    <time_frame>2 hours</time_frame>
    <description>Measure the rate of fluid uptake by the gut using appearance of deuterium oxide, or D2O, in the blood after ingesting a fixed volume of placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of appearance of deuterium in the plasma for oral rehydration solution 2.</measure>
    <time_frame>2 hours</time_frame>
    <description>Measure the rate of fluid uptake by the gut using appearance of deuterium oxide, or D2O, in the blood after ingesting a fixed volume of placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluid retention for placebo</measure>
    <time_frame>2 hours</time_frame>
    <description>Measure fluid retention using the difference between ingested volume and cumulative urine excretion as a percentage of the ingested volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid retention for oral rehydration solution 1</measure>
    <time_frame>2 hours</time_frame>
    <description>Measure fluid retention using the difference between ingested volume and cumulative urine excretion as a percentage of the ingested volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid retention for oral rehydration solution 2</measure>
    <time_frame>2 hours</time_frame>
    <description>Measure fluid retention using the difference between ingested volume and cumulative urine excretion as a percentage of the ingested volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma volume for placebo</measure>
    <time_frame>2 hours</time_frame>
    <description>Increase in plasma volume (water content of the blood) following ingestion of beverage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma volume for oral rehydration solution 1</measure>
    <time_frame>2 hours</time_frame>
    <description>Increase in plasma volume (water content of the blood) following ingestion of beverage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma volume for oral rehydration solution 2</measure>
    <time_frame>2 hours</time_frame>
    <description>Increase in plasma volume (water content of the blood) following ingestion of beverage</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hydration</condition>
  <condition>Fluid Retention</condition>
  <condition>Dehydration</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral rehydration solution 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beverage with 2.5% glucose with 45 mmol sodium/L.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral rehydration solution 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beverage with 1.7% glucose with 60 mmol sodium/L.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ingestion of one (1) liter of beverage with observation for 2 h</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Oral Rehydration Solution 1</intervention_name>
    <description>Ingestion of one (1) liter of beverage with observation for 2 h</description>
    <arm_group_label>Oral rehydration solution 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Oral Rehydration Solution 2</intervention_name>
    <description>Ingestion of one (1) liter of beverage with observation for 2 h</description>
    <arm_group_label>Oral rehydration solution 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a BMI of 18.5 to 29.9 kg/m2.&#xD;
&#xD;
          -  Be normotensive (&lt;120/80 mm Hg).&#xD;
&#xD;
          -  Must be able to speak and read English.&#xD;
&#xD;
          -  Be physically active or a regular exerciser but be able to abstain from exercise for&#xD;
             48 h prior to each study trial.&#xD;
&#xD;
          -  Fast for at least 8 hours prior to and through the study trial.&#xD;
&#xD;
          -  Be able to abstain from alcohol for 48 h prior to each study.&#xD;
&#xD;
          -  Be able to abstain from caffeine for 24 h prior to each study.&#xD;
&#xD;
          -  If female, must have regular menstrual cycles, that are &gt; 27 days and &lt; 35 days in&#xD;
             length.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under 18 y of age or over 45 y of age.&#xD;
&#xD;
          -  Have a BMI &lt;18.5 or &gt;30.&#xD;
&#xD;
          -  Being pregnant.&#xD;
&#xD;
          -  Lactating.&#xD;
&#xD;
          -  Tobacco user.&#xD;
&#xD;
          -  Have hypotension or hypertension.&#xD;
&#xD;
          -  Have any type of kidney disease or dysfunction.&#xD;
&#xD;
          -  Have diabetes.&#xD;
&#xD;
          -  Have any type of cardiovascular disease.&#xD;
&#xD;
          -  Have been diagnosed with galactosemia.&#xD;
&#xD;
          -  Females with irregular menstrual cycles.&#xD;
&#xD;
          -  Females with polycystic ovary disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Horswill, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Horswill, PhD</last_name>
    <phone>312-996-5656</phone>
    <email>horswill@uic.edu</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Craig A. Horswill</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hydration</keyword>
  <keyword>Deuterium oxide</keyword>
  <keyword>Plasma osmolality</keyword>
  <keyword>Sodium</keyword>
  <keyword>Urine production</keyword>
  <keyword>Fluid absorption</keyword>
  <keyword>Euhydration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>If shared, the main outcome variables will be posted.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

